share_log

B of A Securities Maintains Underperform on Fate Therapeutics, Raises Price Target to $6

Moomoo 24/7 ·  Mar 28 14:13

B of A Securities analyst Tazeen Ahmad maintains Fate Therapeutics (NASDAQ:FATE) with a Underperform and raises the price target from $2 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment